Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma

被引:107
作者
Shimada, Kazuaki
Sakamoto, Yoshihiro
Esaki, Minoru
Kosuge, Tomoo
Morizane, Chigusa
Ikeda, Masafumi
Ueno, Hideki
Okusaka, Takuji
Arai, Yasuaki
Takayasu, Kenichi
机构
[1] Natl Canc Ctr, Div Hepatobil & Pancreat Surg, Tokyo, Japan
[2] Natl Canc Ctr, Div Hepatobil & Pancreat Oncol, Tokyo, Japan
[3] Natl Canc Ctr, Div Diagnost Radiol, Tokyo, Japan
关键词
hepatocellular carcinoma; recurrence pattern; repeat hepatectomy; local ablation therapy; transarterial chemoembolization;
D O I
10.1245/s10434-007-9415-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Survival analysis in patients with initial recurrence after curative hepatectomy for hepatocellular carcinoma (HCC) has not been well evaluated. In addition, selections of the most effective treatments for patients with recurrent HCC still remain controversial. Methods: Three hundred and nineteen patients who underwent potentially curative hepatectomies were followed for initial recurrence, and factors predictive of recurrence were determined. The factors affecting survival including pattern of recurrence and treatment modalities from the time of initial recurrence in 211 patients were retrospectively analyzed. Results: The overall 5-year disease-free survival rate of 319 patients was 31.1%. The 5-year survival rate of 211 patients from the time of initial recurrence was 31.9%. In a multivariate analysis, a low indocyanine green retention rate, lack of liver cirrhosis, a long interval before recurrence, the absence of portal vein invasion, and intrahepatic recurrence (<= 3 nodules) were shown to be significantly favorable prognostic factors after the initial recurrence. The 5-year survival rate of patients with intrahepatic recurrence (<= 3 nodules) was 42.3%, and no survival differences were observed among different treatment modalities. Conclusion: When the initial recurrence occurred after a longer interval, and/or with three or fewer intrahepatic recurrent nodules, a favorable prognosis could be expected in those patients with better liver function and no portal vein invasion at the time of the primary hepatectomy. It is important to conduct a randomized controlled trial to clarify a method for selecting optimal treatment in patients with a smaller number of initial intrahepatic recurrences.
引用
收藏
页码:2337 / 2347
页数:11
相关论文
共 40 条
[1]   Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis - Analysis of 48 cases [J].
Ando, E ;
Tanaka, M ;
Yamashita, F ;
Kuromatsu, R ;
Yutani, S ;
Fukumori, K ;
Sumie, S ;
Yano, Y ;
Okuda, K ;
Sata, M .
CANCER, 2002, 95 (03) :588-595
[2]  
ARII S, 1992, CANCER, V69, P913, DOI 10.1002/1097-0142(19920215)69:4<913::AID-CNCR2820690413>3.0.CO
[3]  
2-T
[4]   Seven hundred forty-seven hepatectomies in the 1990s: An update to evaluate the actual risk of liver resection [J].
Belghiti, J ;
Hiramatsu, K ;
Benoist, S ;
Massault, PP ;
Sauvanet, A ;
Farges, O .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2000, 191 (01) :38-46
[5]   Hematogenous spreading of hepatocellular carcinoma cells: Possible participation in recurrence in the liver [J].
Funaki, NO ;
Tanaka, J ;
Seto, SI ;
Kasamatsu, T ;
Kaido, T ;
Imamura, M .
HEPATOLOGY, 1997, 25 (03) :564-568
[6]   Surgical resection for recurrent hepatocellular carcinoma: Prognosis and analysis of risk factors [J].
Hu, RH ;
Lee, PH ;
Yu, SC ;
Dai, HC ;
Sheu, JC ;
Lai, MY ;
Hsu, HC ;
Chen, DS .
SURGERY, 1996, 120 (01) :23-29
[7]   One thousand fifty-six hepatectomies without mortality in 8 years [J].
Imamura, H ;
Seyama, Y ;
Kokudo, N ;
Maema, A ;
Sugawara, Y ;
Sano, K ;
Takayama, T ;
Makuuchi, M .
ARCHIVES OF SURGERY, 2003, 138 (11) :1198-1206
[8]   Improvement in Perioperative outcome after hepatic resection - Analysis of 1,803 consecutive cases over the past decade [J].
Jamagin, WR ;
Gonen, M ;
Fong, YM ;
DeMatteo, RP ;
Ben-Porat, L ;
Little, S ;
Corvera, C ;
Weber, S ;
Blumgart, LH .
ANNALS OF SURGERY, 2002, 236 (04) :397-407
[9]   Percutaneous local ablative therapy for hepatocellular carcinoma - A review and look into the future [J].
Lau, WY ;
Leung, TWT ;
Yu, SCH ;
Ho, SKW .
ANNALS OF SURGERY, 2003, 237 (02) :171-179
[10]   Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial [J].
Lau, WY ;
Leung, TWT ;
Ho, SKW ;
Chan, M ;
Machin, D ;
Lau, J ;
Chan, ATC ;
Yeo, W ;
Mok, TSK ;
Yu, SCH ;
Leung, NWY ;
Johnson, PJ .
LANCET, 1999, 353 (9155) :797-801